Dorie Sher

1.3k total citations
29 papers, 1.0k citations indexed

About

Dorie Sher is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Dorie Sher has authored 29 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 11 papers in Molecular Biology and 11 papers in Genetics. Recurrent topics in Dorie Sher's work include Acute Myeloid Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Dorie Sher is often cited by papers focused on Acute Myeloid Leukemia Research (12 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Dorie Sher collaborates with scholars based in United States, Philippines and Israel. Dorie Sher's co-authors include Wendy Stock, Amelia Bartholomew, Sheila Patil, Terry A. Hewett, Nadim Mahmud, Joseph D. Mosca, Annemarie Moseley, Cord Sturgeon, Scott M. Weissman and Theodore D. Chung and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Dorie Sher

29 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dorie Sher United States 14 463 373 326 298 198 29 1.0k
Sarah Pozzi Italy 14 625 1.3× 300 0.8× 571 1.8× 254 0.9× 296 1.5× 31 1.3k
Mohammad Shahjahani Iran 19 350 0.8× 580 1.6× 463 1.4× 247 0.8× 178 0.9× 67 1.3k
Jan Jansen United States 15 554 1.2× 223 0.6× 380 1.2× 224 0.8× 282 1.4× 36 1.0k
Shihong Lu China 19 387 0.8× 440 1.2× 270 0.8× 198 0.7× 210 1.1× 59 1.1k
Peiyan Kong China 18 281 0.6× 306 0.8× 462 1.4× 308 1.0× 198 1.0× 86 983
Joon Seong Park South Korea 18 303 0.7× 365 1.0× 216 0.7× 277 0.9× 163 0.8× 96 1.0k
Miranda Buitenhuis Netherlands 19 151 0.3× 506 1.4× 391 1.2× 431 1.4× 378 1.9× 30 1.3k
Pedro Lastres Spain 20 306 0.7× 844 2.3× 150 0.5× 254 0.9× 202 1.0× 27 1.6k
Joost W van der Heijden Netherlands 10 101 0.2× 561 1.5× 317 1.0× 301 1.0× 169 0.9× 22 1.1k
Yongxian Hu China 17 140 0.3× 356 1.0× 250 0.8× 485 1.6× 203 1.0× 60 996

Countries citing papers authored by Dorie Sher

Since Specialization
Citations

This map shows the geographic impact of Dorie Sher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dorie Sher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dorie Sher more than expected).

Fields of papers citing papers by Dorie Sher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dorie Sher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dorie Sher. The network helps show where Dorie Sher may publish in the future.

Co-authorship network of co-authors of Dorie Sher

This figure shows the co-authorship network connecting the top 25 collaborators of Dorie Sher. A scholar is included among the top collaborators of Dorie Sher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dorie Sher. Dorie Sher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Chenyu, Anand Patel, Dezheng Huo, et al.. (2024). A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Advances. 8(22). 5735–5743. 1 indexed citations
2.
Poiré, Xavier, Barry Kurt Moser, Robert E. Gallagher, et al.. (2013). Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype. Leukemia & lymphoma. 55(7). 1523–1532. 38 indexed citations
3.
Liu, Hui, Jeffrey L. Johnson, Gregory Malnassy, et al.. (2011). Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 97(4). 579–585. 59 indexed citations
4.
5.
Slovak, Marilyn L., Victoria Bedell, Danika L. Lew, et al.. (2009). Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Research and Treatment. 119(2). 391–398. 12 indexed citations
6.
7.
Odenike, Olatoyosi, Serhan Alkan, Dorie Sher, et al.. (2008). Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia. Clinical Cancer Research. 14(21). 7095–7101. 55 indexed citations
8.
Odenike, Olatoyosi, John E. Godwin, Koen van Besien, et al.. (2008). Phase II Trial of Low Dose, Subcutaneous Decitabine in Myelofibrosis. Blood. 112(11). 2809–2809. 28 indexed citations
9.
Stock, Wendy, Daohai Yu, T. Karrison, et al.. (2006). Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. International Journal of Oncology. 28(5). 1099–103. 21 indexed citations
10.
Stock, Wendy, Richard C. Harvey, Barry Kurt Moser, et al.. (2006). Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.. Blood. 108(11). 494–494. 2 indexed citations
11.
Stock, Wendy, Jeffrey Johnson, Daohai Yu, et al.. (2005). Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802.. Blood. 106(11). 1833–1833. 7 indexed citations
12.
13.
Sher, Dorie, Jeffrey L. Johnson, Michael A. Caligiuri, et al.. (2004). Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma: CALGB 59909.. Blood. 104(11). 1652–1652. 2 indexed citations
14.
Mata‐Greenwood, Eugenia, et al.. (2002). Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-myc. Leukemia. 16(11). 2275–2284. 72 indexed citations
15.
Devine, Steven M., Amelia Bartholomew, Nadim Mahmud, et al.. (2001). Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Experimental Hematology. 29(2). 244–255. 336 indexed citations
16.
Bartholomew, Amelia, Dorie Sher, Wendy Stock, et al.. (2001). STEM CELL TRANSPLANTATION ELIMINATES ALLOANTIBODY IN A HIGHLY SENSITIZED PATIENT1. Transplantation. 72(10). 1653–1655. 14 indexed citations
17.
Besien, Koen van, Amelia Bartholomew, Wendy Stock, et al.. (2000). Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease. Bone Marrow Transplantation. 26(4). 445–449. 77 indexed citations
18.
19.
Walsh, Craig M., Abraham Chachoua, Ruth Oratz, et al.. (1992). Modulation of Monocyte Functions by Muramyl Triptide Phosphatidylethanolamine in a Phase II Study in Patients With Metastatic Melanoma. JNCI Journal of the National Cancer Institute. 84(9). 694–699. 27 indexed citations
20.
Kadouri, A., Dorie Sher, & N.G. Maroudas. (1988). Polystyrene substratum for bulk culture of anchorage dependent cells. Cytotechnology. 1(4). 301–307. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sarah Pozzi Breakdown of academic impact, for papers by Mohammad Shahjahani Breakdown of academic impact, for papers by Jan Jansen Breakdown of academic impact, for papers by Shihong Lu Breakdown of academic impact, for papers by Peiyan Kong Breakdown of academic impact, for papers by Joon Seong Park Breakdown of academic impact, for papers by Miranda Buitenhuis Breakdown of academic impact, for papers by Pedro Lastres Breakdown of academic impact, for papers by Joost W van der Heijden Breakdown of academic impact, for papers by Yongxian Hu
Rankless by CCL
2026